InnoCare Pharma (HKSE:09969) Margin of Safety % (DCF Dividends Based): N/A (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09969 InnoCare Pharma Ltd HKSE:09969
83 GF Score
Price HK$14.27
GF Value HK$21.38
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is InnoCare Pharma Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

InnoCare Pharma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

HKSE:09969 vs VRTX, REGN, RVMD: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, InnoCare Pharma's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCare Pharma Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's Margin of Safety % (DCF Dividends Based) falls into.


HKSE:09969
83GF Score
InnoCare Pharma Ltd HKSE:09969
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is InnoCare Pharma (HKSE:09969) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued. The current stock price of HK$14.27 is trading 33.3% below its estimated GF Value™ of HK$21.38. GuruFocus considers InnoCare Pharma to be Possible Value Trap.

Key valuation signals for HKSE:09969:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: HK$21.38 vs. price of HK$14.27 (33.3% below fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the HKSE:09969 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCare Pharma Business Description

Other Exchanges 33C:Germany688428:China
Address No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
83GF Score

Get the complete analysis for HKSE:09969

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$14.27
Price
HK$21.38
GF Value